[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-337985-105":3,"detail-sidebar-cat-0-en-105":77,"doc-detail-337985-en":126},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":70,"head_meta":72,"extra_data":74,"updated_unix":76},105,"en","autotaxinlysophosphatidate-axis-promoter-of-cancer-development-and-possible-therapeutic-implications","Autotaxin–Lysophosphatidate Axis - Promoter of Cancer Development and Possible Therapeutic Implications","","Autotaxin (ATX), encoded by ENPP2, is a secreted glycoprotein that converts lysophosphatidylcholine (LPC) into lysophosphatidic acid (LPA). LPA signals through at least six G protein-coupled receptors (LPAR1–6) and participates in multiple physiological and pathological processes, including angiogenesis, embryonic development, inflammation, fibrosis, and obesity. Accumulating evidence links the ATX–LPA axis to carcinogenesis, immune escape, metastasis, tumor microenvironment remodeling, cancer stem cells, and therapy resistance. This review synthesizes its role as a driver of cancer development, progression, invasion, and explores biomarker/therapeutic targeting potential.",{"@graph":14,"@context":69},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/autotaxinlysophosphatidate-axis-promoter-of-cancer-development-and-possible-therapeutic-implications/337985/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/autotaxinlysophosphatidate-axis-promoter-of-cancer-development-and-possible-therapeutic-implications/337985.png","ImageObject",300,407,{"name":42,"@type":43},"Liam","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-04","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",9,{"@type":57,"mainEntity":58},"FAQPage",[59,65],{"name":60,"@type":61,"acceptedAnswer":62},"What is the ATX–LPA axis and how does it work?","Question",{"text":63,"@type":64},"Autotaxin (ATX) encoded by ENPP2 hydrolyzes lysophosphatidylcholine (LPC) to produce lysophosphatidic acid (LPA). LPA then transduces signals via at least six G protein-coupled receptors (LPAR1–6).","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How does the ATX–LPA axis relate to cancer and treatment outcomes?",{"text":68,"@type":64},"Evidence links the ATX–LPA axis to carcinogenesis, immune escape, metastasis, tumor microenvironment, cancer stem cells, and therapeutic resistance. The review highlights its potential as a prognostic/predictive biomarker and therapeutic target.","https://schema.org",{"og:url":32,"og:type":71,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":73,"canonical":32},"index,follow",{"doc_id":75,"site_id":7},337985,1790536121,{"code":4,"msg":78,"data":79},"success",[80,84,88,92,97,102,107,111,115,118,122],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":81,"show_sort_weight":82,"slug":83},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Exam",70,"exam",{"id":93,"doc_module":4,"doc_module_name":25,"category_name":94,"show_sort_weight":95,"slug":96},5,"Comic",60,"comic",{"id":98,"doc_module":4,"doc_module_name":25,"category_name":99,"show_sort_weight":100,"slug":101},6,"Technology",50,"technology",{"id":103,"doc_module":4,"doc_module_name":25,"category_name":104,"show_sort_weight":105,"slug":106},7,"Healthcare",40,"healthcare",{"id":108,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":109,"slug":110},8,30,"research-report",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":112,"show_sort_weight":113,"slug":114},"Religion & Spirituality",20,"religion-spirituality",{"id":113,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":113,"slug":117},"World Cup","world-cup",{"id":119,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":119,"slug":121},10,"Lifestyle","lifestyle",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":93,"slug":125},19,"General","general",{"code":4,"msg":78,"data":127},{"doc_id":75,"user_id":128,"nickname":42,"user_avatar":129,"doc_module":4,"category_id":108,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":130,"file_id":131,"file_url":132,"file_type":133,"file_size":134,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":135,"language":136,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":137,"faqs":138,"seo_title":139,"seo_description":12,"update_tm":140,"read_time":141,"preview_page_count":33,"preview_urls":142},8796095461564,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","Review  \nAutotaxin–Lysophosphatidate Axis: Promoter of Cancer Development and Possible Therapeutic Implications  \nCarmelo Laface 1,*, Angela Dalia Ricci 1, Simona Vallarelli 1, Carmela Ostuni 1, Alessandro Rizzo 2, Francesca Ambrogio 3, Matteo Centonze 4, Annalisa Schirizzi 5, Giampiero De Leonardis 5, Rosalba D’Alessandro 5, Claudio Lotesoriere 1, * and Gianluigi Giannelli 6  \nCitation: Laface, C.; Ricci, A.D.; Vallarelli, S.; Ostuni, C.; Rizzo, A.; Ambrogio, F.; Centonze, M.; Schirizzi, A.; De Leonardis, G.; D’Alessandro, R.; et al. Autotaxin–Lysophosphatidate Axis: Promoter of Cancer Development and Possible Therapeutic Implications. Int. J. Mol. Sci. 2024, 25, 7737 . [https://doi.org/10.3390/](https://doi.org/10.3390/)[ ](https://doi.org/10.3390/)ijms25147737  \nAcademic Editor: Elena Andreucci  \nReceived: 30 May 2024  \nRevised: 3 July 2024  \nAccepted: 11 July 2024  \nPublished: 15 July 2024  \nCopyright: © 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ([https://](https://)[ ](https://)[creativecommons.org/licenses/by/](creativecommons.org/licenses/by/)[ ](creativecommons.org/licenses/by/)[4.0/](4.0/)) .  \n1 Medical Oncology Unit, National Institute of Gastroenterology, IRCCS “S. de Bellis” Research Hospital, 70013 Castellana Grotte, Italy  \n2 Medical Oncology, IRCCS Istituto Tumori “Giovanni Paolo II”, Viale Orazio Flacco 65, 70124 Bari, Italy  \n3 Section of Dermatology and Venereology, Department of Precision and Regenerative Medicine and Ionian Area (DiMePRe-J), University of Bari “Aldo Moro”, 70124 Bari, Italy  \n4 Personalized Medicine Laboratory, National Institute of Gastroenterology, IRCCS “S. de Bellis” Research Hospital, 70013 Castellana Grotte, Italy; matteo.centonze@irccsdebellis.it  \n5 Laboratory of Experimental Oncology, National Institute of Gastroenterology,“IRCCS “S. de Bellis” Research Hospital, 70013 Castellana Grotte, Italy; [annalisa.schirizzi@irccsdebellis.it](annalisa.schirizzi@irccsdebellis.it) (A.S.); [giampiero.deleonardis@irccsdebellis.it](giampiero.deleonardis@irccsdebellis.it) (G.D.L.)  \n6 Scientific Direction, National Institute of Gastroenterology, IRCCS “S. de Bellis” Research Hospital,  \n70013 Castellana Grotte, Italy  \n* Correspondence: [carmelo.laface@irccsdebellis.it](carmelo.laface@irccsdebellis.it) (C.L.); [claudio.lotesoriere@irccsdebellis.it](claudio.lotesoriere@irccsdebellis.it) (C.L.)  \nAbstract: Autotaxin (ATX) is a member of the ectonucleotide pyrophosphate/phosphodiesterase (ENPP) family; it is encoded by the ENPP2 gene. ATX is a secreted glycoprotein and catalyzes the hydrolysis of lysophosphatidylcholine to lysophosphatidic acid (LPA) . LPA is responsible for the transduction of various signal pathways through the interaction with at least six G protein-coupled receptors, LPA Receptors 1 to 6 (LPAR1–6) . The ATX–LPA axis is involved in various physiological and pathological processes, such as angiogenesis, embryonic development, inflammation, fibrosis, and obesity. However, significant research also reported its connection to carcinogenesis, immune escape, metastasis, tumor microenvironment, cancer stem cells, and therapeutic resistance. Moreover, several studies suggested ATX and LPA as relevant biomarkers and/or therapeutic targets. In this review of the literature, we aimed to deepen knowledge about the role of the ATX–LPA axis as a promoter of cancer development, progression and invasion, and therapeutic resistance. Finally, we explored its potential application as a prognostic/predictive biomarker and therapeutic target for tumor treatment.  \nKeywords: autotaxin (ATX); ENPP2; lysophospholipase D (lysoD); lysophosphatidic acid (LPA); lysophosphatidylcholine (LPC); ATX-LPA axis; tumor microenvironment; cancer  \n1. Introduction  \nAutotaxin (ATX) is a glycoprotein, a member of the ectonucleotide pyrophosphate/ phosphodiesterase (ENPP) fam","cbCaig1XjZ5dnlXz","https://ap.wps.com/l/cbCaig1XjZ5dnlXz","pdf",2830138,26,"English","# Abstract\n# Keywords\n# Introduction\n## ATX–LPA signaling overview\n## Roles in physiology and pathology\n# Review aims and focus\n## Cancer development, progression, invasion\n## Therapeutic resistance and targeting potential","[{\"question\":\"What is the ATX–LPA axis and how does it work?\",\"answer\":\"Autotaxin (ATX) encoded by ENPP2 hydrolyzes lysophosphatidylcholine (LPC) to produce lysophosphatidic acid (LPA). LPA then transduces signals via at least six G protein-coupled receptors (LPAR1–6).\"},{\"question\":\"How does the ATX–LPA axis relate to cancer and treatment outcomes?\",\"answer\":\"Evidence links the ATX–LPA axis to carcinogenesis, immune escape, metastasis, tumor microenvironment, cancer stem cells, and therapeutic resistance. The review highlights its potential as a prognostic/predictive biomarker and therapeutic target.\"}]","Autotaxin–Lysophosphatidate Axis - Promoter of Cancer Development and Possible Therapeutic Implications | PDF",1790021425,66,[143,147,151,155],{"page_no":22,"url":144,"width":145,"height":146},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/59fe0fb7b151a296fe975dbb01fecbcc.webp",983,1390,{"page_no":26,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6b2180b7652573b341238703bf602304.webp",982,1388,{"page_no":30,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0911144b9c5029901266cf1cd020ef30.webp",981,1387,{"page_no":33,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/83fd8422af05bc63d252f9555d083f6b.webp",980,1385]